COVID-19 Impact on Musculoskeletal Regenerative Medicine Research: Maintaining Lab Continuity.

COVID-19 control measures regenerative medicine risk assessment

Journal

International journal of environmental research and public health
ISSN: 1660-4601
Titre abrégé: Int J Environ Res Public Health
Pays: Switzerland
ID NLM: 101238455

Informations de publication

Date de publication:
05 Jun 2021
Historique:
received: 30 03 2021
revised: 20 05 2021
accepted: 02 06 2021
entrez: 2 7 2021
pubmed: 3 7 2021
medline: 8 7 2021
Statut: epublish

Résumé

Research in the fields of musculoskeletal tissue engineering and regenerative medicine may suffer a slowdown during the ongoing COVID-19 pandemic emergency. This is likely to harm the development of new therapeutic strategies and their translation into the clinic in the long term. Recently, the need to maintain continuity in research activities in those fields has assumed even greater importance due to the accumulation of data concerning the effects of SARS-CoV-2 on the musculoskeletal system. This study is aimed at the identification of a series of safe handling practices against COVID-19 diffusion to apply in a research environment, thus allowing the maintenance of research lab activities. The control measures to apply to mitigate the COVID-19 risk were identified and categorized utilizing the Hierarchy of Controls. We also compared our analysis with that assessed before the pandemic to consider the additional risk of COVID-19. Results highlighted that the most relevant implemented measures to control SARS-CoV-2 were based on protecting people through engineering (e.g., ventilation and social distancing), and administrative (e.g., hand sanitization, work shifts) measures or Personnel Protective Equipment, rather than eliminating hazards at the source (e.g., smart working). Work continuity in research labs during the COVID-19 emergency should be guaranteed by ensuring the protection of researchers in the workplace and considering the physical environment, the type of operators and work activity, and the proven ability of workers to face biological risks. The increased knowledge and awareness on lab' risks should be useful to prevent and mitigate future viral outbreaks.

Sections du résumé

BACKGROUND BACKGROUND
Research in the fields of musculoskeletal tissue engineering and regenerative medicine may suffer a slowdown during the ongoing COVID-19 pandemic emergency. This is likely to harm the development of new therapeutic strategies and their translation into the clinic in the long term. Recently, the need to maintain continuity in research activities in those fields has assumed even greater importance due to the accumulation of data concerning the effects of SARS-CoV-2 on the musculoskeletal system. This study is aimed at the identification of a series of safe handling practices against COVID-19 diffusion to apply in a research environment, thus allowing the maintenance of research lab activities.
METHODS METHODS
The control measures to apply to mitigate the COVID-19 risk were identified and categorized utilizing the Hierarchy of Controls. We also compared our analysis with that assessed before the pandemic to consider the additional risk of COVID-19.
RESULTS RESULTS
Results highlighted that the most relevant implemented measures to control SARS-CoV-2 were based on protecting people through engineering (e.g., ventilation and social distancing), and administrative (e.g., hand sanitization, work shifts) measures or Personnel Protective Equipment, rather than eliminating hazards at the source (e.g., smart working).
CONCLUSIONS CONCLUSIONS
Work continuity in research labs during the COVID-19 emergency should be guaranteed by ensuring the protection of researchers in the workplace and considering the physical environment, the type of operators and work activity, and the proven ability of workers to face biological risks. The increased knowledge and awareness on lab' risks should be useful to prevent and mitigate future viral outbreaks.

Identifiants

pubmed: 34198945
pii: ijerph18116110
doi: 10.3390/ijerph18116110
pmc: PMC8201300
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : 5x1000 funds (Cirizen donation, non grant number), Italian Ministry of Health "Sviluppo di un device stampato in 3D per l'inserzione tibiale del legamento crociato anteriore"
ID : 000

Références

Saf Sci. 2021 Jan;133:104995
pubmed: 32982065
Tissue Eng Part A. 2020 May;26(9-10):468-474
pubmed: 32272857
Virusdisease. 2020 Jun;31(2):161-173
pubmed: 32656310
Nat Rev Microbiol. 2021 Mar;19(3):141-154
pubmed: 33024307
Int Orthop. 2020 Oct;44(10):2189-2190
pubmed: 32767087
Osteoarthritis Cartilage. 2020 Mar;28(3):242-248
pubmed: 31945457
Bone Joint Res. 2020 Aug 2;9(8):531-533
pubmed: 32922761
Ann Intern Med. 2021 Jan;174(1):69-79
pubmed: 32941052
Comp Med. 2017 Jun 1;67(3):192-202
pubmed: 28662748
Adv Drug Deliv Rev. 2021 Mar;170:1-25
pubmed: 33359141
J Bone Joint Surg Am. 2020 Jul 15;102(14):1205-1212
pubmed: 32675662
Front Public Health. 2020 Jul 29;8:383
pubmed: 32850602
Int J Environ Res Public Health. 2021 Feb 23;18(4):
pubmed: 33672294
Lancet Glob Health. 2020 Nov;8(11):e1368
pubmed: 32986980
Nat Microbiol. 2020 Aug;5(8):986
pubmed: 32710091
J Infect Public Health. 2020 May;13(5):667-673
pubmed: 32340833
Stem Cells Transl Med. 2021 Jan;10(1):27-38
pubmed: 32820868
Front Neurol. 2020 Jun 26;11:687
pubmed: 32676052
Process Biochem. 2020 Nov;98:233-240
pubmed: 32843849
J Bone Joint Surg Am. 2020 Jul 15;102(14):1197-1204
pubmed: 32675661
Saf Sci. 2020 Aug;128:104773
pubmed: 32296266
PLoS Pathog. 2020 Sep 30;16(9):e1008898
pubmed: 32997719

Auteurs

Livia Roseti (L)

IRCCS Istituto Ortopedico Rizzoli, SSD RAMSES, Via di Barbiano 1/10, 40136 Bologna, Italy.

Brunella Grigolo (B)

IRCCS Istituto Ortopedico Rizzoli, SSD RAMSES, Via di Barbiano 1/10, 40136 Bologna, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH